- Home
- SNGX vs IBO Comparison
SNGX vs IBO Comparison
Compare SNGX & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- IBO
- Stock Information
- Founded
- SNGX 1987
- IBO 2018
- Country
- SNGX United States
- IBO United States
- Employees
- SNGX N/A
- IBO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- IBO
- Sector
- SNGX Health Care
- IBO
- Exchange
- SNGX Nasdaq
- IBO NYSE
- Market Cap
- SNGX 6.5M
- IBO 5.8M
- IPO Year
- SNGX 1987
- IBO 2024
- Fundamental
- Price
- SNGX $1.36
- IBO $0.64
- Analyst Decision
- SNGX Strong Buy
- IBO
- Analyst Count
- SNGX 1
- IBO 0
- Target Price
- SNGX $6.00
- IBO N/A
- AVG Volume (30 Days)
- SNGX 2.7M
- IBO 23.5M
- Earning Date
- SNGX 08-08-2025
- IBO 08-23-2025
- Dividend Yield
- SNGX N/A
- IBO N/A
- EPS Growth
- SNGX N/A
- IBO N/A
- EPS
- SNGX N/A
- IBO N/A
- Revenue
- SNGX $2,342.00
- IBO N/A
- Revenue This Year
- SNGX N/A
- IBO N/A
- Revenue Next Year
- SNGX N/A
- IBO N/A
- P/E Ratio
- SNGX N/A
- IBO N/A
- Revenue Growth
- SNGX N/A
- IBO N/A
- 52 Week Low
- SNGX $1.09
- IBO $0.36
- 52 Week High
- SNGX $7.20
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- SNGX 44.21
- IBO N/A
- Support Level
- SNGX $1.24
- IBO N/A
- Resistance Level
- SNGX $1.40
- IBO N/A
- Average True Range (ATR)
- SNGX 0.14
- IBO 0.00
- MACD
- SNGX 0.03
- IBO 0.00
- Stochastic Oscillator
- SNGX 34.18
- IBO 0.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.